Sign up
Pharma Capital

Avenue Therapeutics anticipates filing for FDA approval of its pain drug by end of 2019

Avenue Therapeutics (NASDAQ:ATXI) CEO Lucy Lu tells Proactive Investors the New York City based biopharma is developing a post-surgical pain management drug called IV Tramadol, which is currently in Phase 3 testing.

Lu explains the drug can be used instead of conventional narcotics, only with less abuse potential as it has two ways of inhibiting pain.

Lu says the company anticipates the company will be on track to file a New Drug Application for IV Tramadol by the end of 2019.

 

View full ATXI profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.